Telmisartan inhibits human urological cancer cell growth through early apoptosis

Experimental and Therapeutic Medicine

Volumn 1, Issue 2, 2010, Pages 301-306

  Matsuyama, Masahide ^a   Funao, Kiyoaki ^b   Kuratsukuri, Katsuyuki ^b   Tanaka, Tomoaki ^b   Kawahito, Yutaka ^c   Sano, Hajime ^d   Jamel, Chargui ^a   Touraine, Jean Louis ^a   Yoshimura, Norio ^c   Yoshimura, Rikio ^b  

^a UNIVERSITÉ LYON 1   (France)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Apoptosis; Telmisartan; Urological cancer

Indexed keywords

CANDESARTAN; IRBESARTAN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; VALSARTAN;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PROSTATE CANCER; TESTIS CANCER; URINARY TRACT CANCER;

EID: 77956203605     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000046     Document Type: Article

References (35)

1. Weidner N, Folkman J, Pozza F, Bevilaqua P, Allred EN and Moore DH: Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
2. Lafyatis R, Thompson NL, Remmers EF, Flanders KC, Roche NS and Kim SJ: Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. J Immunol 143: 1142-1148, 1989.
3. Kubota T, Koshizuka K, Williamson EA, et al: Ligand for Peroxisome proliferator-activated receptor-γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998.
4. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998.
5. See S and Stirling AL: Candesartan cilexetil: an angiotensin II receptor blocker. Am J Health Syst Pharm 57: 739-746, 2000.
6. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
7. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
8. Le Noble FA, Hekking JW, van Straaten HW, Slaaf DW and Struyker Boudier HA: Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol 195: 305-306, 1991.
9. Le Noble FA, Schreurs NH, van Straaten HW, et al: Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioal-lantoic membrane. Am J Physiol 264: 460-465, 1993.
10. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43: 993-1002, 2004.
11. Inoue K, Kawahito Y, Tsubouchi Y, et al: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 287: 727-732, 2001.
12. Yoshimura R, Matsuyama M, Segawa Y, et al: Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 104: 597-602, 2003.
13. Segawa Y, Yoshimura R, Hase T, et al: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51: 108-116, 2002.
14. Hase T, Yoshimura R, Mitsuhashi M, et al: Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 60: 542-547, 2002.
15. Yoshimura R, Matsuyama M, Hase T, et al: The effect of peroxisome proliferator-activated receptor-γ ligand on urological cancer cells. Int J Mol Med 12: 861-865, 2003.
16. Burnier M: Angiotensin II type 1 receptor blockers. Circulation 103: 904-912, 2001.
17. Dina R and Jafari M: Angiotensin II-receptor antagonists. Am J Health-Syst Pharm 57: 1231-1241, 2000.
18. Abali H, Güllü IH, Engin H, Haznedaroǧlu IC, Erman M and Tekuzman G: Old antihypertensive as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med Hypotheses 59: 344-348, 2002.
19. Fujimoto Y, Sasaki T, Tsuchida A and Chayama K: Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495: 197-200, 2001.
20. Miyajima A, Kosaka T, Asano T, et al: Angiotensin II type 1 antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62: 4176-4179, 2002.
21. Goldfarb DA, Diz DI, Tubbs RR, Ferrario CM and Novick AC: Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol 151: 208-213, 1994.
22. Inwang ER, Puddefoot JR, Brown CL, et al: Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 75: 1279-1283, 1997.
23. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y and Murai M: Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 12: 2888-2893, 2006.
24. Kosaka T, Miyajima A, Takayama E, et al: Angiotensin II type I receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67: 41-49, 2007.
25. Egami K, Murohara T, Shimada T, et al: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75, 2003.
26. Koh WP, Yuan JM, van Den Berg D, Lee HP and Yu MC: Polymorphisms in angiotensin II type 1 receptor and angiotensin I converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26: 459-464, 2005.
27. Uemura H, Hasumi H, Kawahara T, et al: Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 10: 405-410, 2005.
28. Kawahito Y, Kondo M, Tsubouchi Y, et al: 15-deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106: 189-197, 2000.
29. Tsubouchi Y, Sano H, Kawahito Y, et al: Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun 270: 400-405, 2000.
30. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G and Wahli W: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68: 879-887, 1992.
31. Kliewer SA, Umesono K, Noonan DJ, Heyman RA and Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774, 1992.
32. Kliewer SA, Forman BM, Blumberg B, et al: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359, 1994.
33. Chinetti G, Griglio S, Antonucci M, et al: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573-25580, 1998.
34. Altiok S, Xu M and Spiegelman BM: PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 11: 1987-1998, 1997.
35. Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS and Mitchell MD: 15-Deoxy-delta (12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 262: 579-585, 1999.